Skip to main content
PMC home page
Cell Death & Disease logoLink to Cell Death & Disease
. 2015 Jul 2;6(7):e1804. doi: 10.1038/cddis.2015.118

Conversion of cell-survival activity of Akt into apoptotic death of cancer cells by two mutations on the BIM BH3 domain

J-S Kim 1,3, B Ku 2,3,3, T-G Woo 4, A-Y Oh 4, Y-S Jung 4, Y-M Soh 2, J-H Yeom 5, K Lee 5, B-J Park 4,*, B-H Oh 2,*, N-C Ha 1,*
PMCID: PMC4650712  PMID: 26136077

Abstract

Survival and proliferation of cancer cells are often associated with hyperactivity of the serine/threonine kinase, Akt. Herein, we show that prosurvival activity of Akt can be converted into prodeath activity by embedding an Akt recognition sequence in the apoptogenic BH3 domain of human BIM. The recognition sequence was created by introducing two mutations, I155R and E158S, into the core region of the BIM BH3 domain. Although a 21-mer BIM BH3 peptide containing these two mutations bound weakly to BCL-XL and BCL-2, this peptide with phosphorylation of Ser158 bound to these proteins with a dissociation constant of <10 nM. The crystal structure of the phosphorylated peptide bound to BCL-XL revealed that the phospho-Ser158 makes favorable interactions with two BCL-XL residues, which cannot be formed with unphosphorylated Ser158. Remarkably, the designed peptide showed a cytotoxic effect on PTEN-null PC3 tumor cells whose Akt activity is aberrantly high. The cell-killing activity disappeared when the cellular Akt activity was lowered by ectopic PTEN expression. Thus, these results lay a foundation for developing a peptide or protein agent that is dormant in normal cells but is transformed into a potent apoptogenic molecule upon phosphorylation by hyperactivity of Akt in cancer cells.

The interplay between the BCL-2 family proteins regulates mitochondrion-mediated apoptotic cell death.1, 2 The BCL-2 family proteins are characterized by having at least one BCL-2 homology (BH) domain, and they are classified into three distinct subgroups based on their functional and structural features. One subgroup consists of BAX and BAK, which contain the BH1-BH4 domains and mediate apoptosis by increasing the permeability of the mitochondrial outer membrane (MOM) and thus leading to the release of the apoptogenic factors, such as cytochrome c and Smac/Diablo.3, 4, 5, 6 Another subgroup is composed of antiapoptotic proteins, BCL-2, BCL-XL, BCl-w, MCL-1, A1 and BCL-B, which contain the BH1-BH4 domains that are arranged to form an extended hydrophobic groove known as the BH3-binding groove.7 The remaining subgroup is composed of a diverse set of proteins that are unrelated to each other except for the possession of the BH3 domain.7 These BH3-only proteins sense and convey apoptotic cell death signals, ultimately leading to the activation of BAX and BAK.8, 9 The antiapoptotic BCL-2 subfamily proteins bind the BH3 domain of BAX/BAK and of the BH3-only proteins through their BH3-binding groove.10, 11, 12, 13, 14, 15

Biochemical studies have discovered that a number of the BH3-only proteins termed ‘activators', such as BID and BIM, bind directly to BAX and induce its activation, whereas other BH3-only proteins termed ‘sensitizers' induce apoptosis by releasing the activators sequestered by the antiapoptotic proteins.5, 16, 17 A recent crystallographic study revealed that the BID BH3 peptide binds to the canonical BH3-binding groove of BAX and induces a pronounced conformational change that exposes the BH3 domain of BAX.18 The activated BAX oligomerizes to induce the permeabilization of the MOM.6 The antiapoptotic BCL-2 proteins were suggested to sequester the BH3 domains of both BAX and the activator BH3-only proteins to prevent the BAX oligomerization.18

Apoptosis is attenuated in cancer cells because of the abundance of antiapoptotic BCL-2 proteins and/or prevention of apoptosis induction. Anticancer BH3 peptides have been developed, especially those derived from BIM, which interacts with all of the antiapoptotic proteins with extremely high affinity.15, 19 These BH3 peptides exhibit a broad and multimodal targeting of the BCL-2 family proteins.20, 21, 22 Promising small molecular anticancer compounds have also been developed that mimic the BH3 peptides and bind to the surface groove of the antiapoptotic proteins.23 ABT-737 and ABT-263 selectively bind to and lower the amounts of the functional BCL-2, BCL-XL and BCL-w proteins to induce the apoptotic death of tumor cells that depend especially on the overexpression of the three proteins.24, 25 The BH3 peptides and the BH3 mimetics both bear an intrinsic shortcoming in that they inhibit the BCL-2 family proteins not only in cancer cells but also in normal cells as they cannot distinguish cancerous from normal cells.

One of the hallmarks of many cancer and tumor cells is the hyperactivation of the serine/threonine (Ser/Thr) protein kinase Akt, which is a key signaling molecule in the cellular survival pathway.26 In many types of cancers, including glioma, prostate cancer and breast cancer, Akt is required to maintain a proliferative state and for progression into a more malignant state in conjunction with genetic mutations.26, 27, 28

We set out to develop a molecule that can respond to the hyperactivity of Akt and can lead to the death of cancer cells. Herein, we describe the embedment of the Akt recognition sequence into the BIM BH3 peptide and the cancer cell-specific apoptogenic property of the resulting BIM BH3 peptide variant characterized by X-ray crystallography, calorimetry and cell-based biochemistry.

Results

Design of a BIM BH3 peptide with an Akt recognition sequence

We chose the BIM BH3 as the template sequence for mutagenesis. According to the crystal structure of the mouse BIM BH3 domain bound to BCL-XL, 21 residues of BIM form the core region of the BH3 domain that spans the surface groove of BCL-XL.14 The 21 residues correspond to 145-EIWIAQELRRIGDEFNAYYAR-165 of human BIM, which is referred to as BH3BIM (Figure 1). To design a BH3BIM peptide variant that can be phosphorylated by Akt, we noted Glu158 in BH3BIM. Glu158 is not a strictly conserved residue, but is involved in a polar interaction with Tyr101, a conserved residue of BCL-XL in the crystal structure,14 suggesting that this residue contributes to the binding affinity of BH3BIM. Thus, it was expected that a BH3BIM variant containing serine in place of Glu158 would exhibit reduced binding affinity for the antiapoptotic BCL-2 family proteins, but phosphorylation of Ser158 could restore the binding affinity since phosphorylated serine often serves as a mimic of glutamate residue. Importantly, this variant peptide turns into an Akt recognition sequence by a second mutation of Ile155Arg, because the doubly mutated sequence has a RRR155GDS158F stretch that conforms to the Akt recognition sequence (RxRxxT/SF; T/S, phosphorylation site).29 Ile155 of human BIM, which is a strictly conserved residue, is involved in extensive hydrophobic interactions with BCL-XL in the complex between mouse BCL-XL and a BIM BH3 peptide.14 Nonetheless, a modeling experiment with this BH3BIM peptide variant, referred to as BH3BIM(I155R/E158S), indicated that arginine in place of Ile155 is sterically compatible and does not completely abrogate the binding interaction. In addition, its guanidinium group seemed to form an intramolecular salt bridge with Glu151 in this peptide.

Figure 1.

Figure 1

Open in a new tab

Amino acid sequences of the peptides used in this study. The substituted residues are in red, and ‘pS' stands for the phosphorylated serine residue

In particular, phosphorylated Ser158, not Ser158, of BIM appeared to form a polar interaction with Tyr101 of BCL-XL. Furthermore, the phosphate group on Ser158 was within the intramolecular ionic-bonding distance from the guanidinium group of Arg154. Based on these expectations, we hypothesized that unphosphorylated BH3BIM(I155R/E158S) would suffer from reduction in the binding affinity compared with the wild-type version, but phosphorylation of the peptide at Ser158 could provide some compensation by directly interacting with BCL-XL. Thus, it seemed plausible that a full-length BIM or a BH3 region bearing the I155R and E158S substitutions could be phosphorylated in cancer cells with elevated Akt activity and then be converted into a potent inhibitor against antiapoptotic BCL-2 proteins, while they are not potentiated in normal cells due to low or controlled Akt activity.

BH3BIM(I155R/E158S) is phosphorylated by Akt and potently binds to antiapoptotic BCL-2 proteins

To examine whether the designed sequence is phosphorylated by Akt as we intended, we carried out an in vitro Akt activity assay by using GST-tagged BH3BIM(I155R/E158S) as the substrate in the presence of [γ-32P]ATP. GST-tagged BH3BIM(I155R/E158S) was efficiently phosphorylated, while GST and GST-tagged BH3BIM(I155R/E158A) employed as controls were not phosphorylated (Figure 2), demonstrating that Ser158 in BH3BIM(I155R/E158S) is specifically phosphorylated by Akt.

Figure 2.

Figure 2

Open in a new tab

In vitro Akt kinase assay. GST-fused BH3BIM(I155R/E158S) (WT), BH3BIM(I155R/E158A) (Ala) or GST was incubated with ATP and [γ-32P]ATP in the presence or absence of Akt. The mixtures were resolved on a SDS-polyacrylamide gel, and the radioactivity (left panel) and Coomassie-staining (right panel) are shown. Only GST-fused BH3BIM(I155R/E158S) was phosphorylated

To test if phosphorylated BH3BIM(I155R/E158S) binds to the BCL-2 family proteins more tightly than its unphosphorylated version, we produced recombinant BCL-2 and BCL-XL proteins, and also prepared two 21-mer synthetic peptides: BH3BIM(I155R/E158S) and phosphorylated BH3BIM(I155R/E158S) at Ser158, which is referred to as p-BH3BIM(I155R/E158S) (Figure 1). Quantification of the binding affinities by isothermal titration calorimetry (ITC) showed that p-BH3BIM(I155R/E158S) interacted potently with BCL-2 and BCL-XL with KD values of 8.55 and 9.90 nM, respectively (Figures 3a and b), similar to that of a longer 36-mer BIM BH3 peptide (KD of ~7 nM).15 In contrast, the unphosphorylated BH3BIM(I155R/E158S) peptide exhibited much lower affinities for the two proteins (KD of 192 and 189 nM, respectively) (Figures 3c and d). Thus, phosphorylated Ser158 appeared to replace the role of Glu158 in the BH3 sequence. Furthermore, the substitution of the conserved hydrophobic Ile155 seemed to be tolerated in the binding reaction, which is intriguing given the observation that an alanine substitution of the corresponding Ile81 residue in a BAK BH3 peptide resulted in a significant reduction of the binding affinity for BCL-XL (KD value changed from 0.34 to 17 μM).30

Figure 3.

Figure 3

Open in a new tab

Phosphorylation-dependent binding of BH3BIM(I155R/E158S) to BCL-2 and BCL-XL. (a–d) The ITC analyses were carried out by titrating the indicated peptides (0.2 mM) into BCL-2 or BCL-XL (20 μM). The KD values were deduced from curve fittings of the integrated heat per mole of added ligand (insets). (e) Competition assay. The BH3BIM(I155R/E158S) peptide was incubated with cell lysate containing overexpressed Akt (wild type (WT), constitutively active form (CA) or kinase-dead (KD) mutant) and HA-tagged BCL-2 protein. This mixture was incubated with GST-PUMA bound to glutathione agarose resin. After washing, bound HA-tagged BCL-2 was detected by immunoblotting. Detection of p-S9-GSK3β was to monitor the Akt activity. Input: used cell lysates and GST-PUMA. EV: empty vector transfection. Numbers: approximate molecular weight

The measured binding affinities of p-BH3BIM(I155R/E158S) for BCL-2 or BCL-XL are comparable to or higher than those of 36-mer BH3 peptides derived from BAX and BAK (KD of 8.1–255 nM),15 suggesting that the phosphorylated BH3BIM(I155R/E158S) sequence, but not the unphosphorylated sequence, could displace these two apoptosis mediators from the antiapoptotic BCL-2 proteins and potentiate cell death. We indirectly tested this possibility by employing PUMA and BCL-2, whose intermolecular interaction is tighter than that between BAX (or BAK) and BCL-2,15 to obviate complications in using full-length BAX or BAK. Recombinant human PUMA fused to GST (GST-PUMA) was produced, and HEK293 cells were prepared to transiently overexpress BCL-2 and one of the three forms of Akt: wild-type, constitutively active or kinase-dead form. Each cell lysate was incubated with BH3BIM(I155R/E158S) and GST-PUMA. This peptide added to the cell lysate containing the wild-type and constitutively active form of Akt abolished the binding between BCL-2 and GST-PUMA, whereas the same peptide added to the cell lysate containing the kinase-dead form of Akt did not interfere with the binding interaction (Figure 3e). The kinase activity of the Akt proteins were confirmed by examining the phosphorylation of GSK3β, a cellular substrate of Akt (Figure 3e). Collectively, these results indicated that Akt-phosphorylated BH3BIM(I155R/E158S), and the phosphorylated peptide could compete with PUMA for binding to BCL-2, whereas the unphosphorylated peptide could not.

Structure of BCL-XL in a complex with p-BH3BIM(I155R/E158S)

To understand the structural basis for the critical role of the Ser158 phosphorylation, we next determined the crystal structure of BCL-XL bound to p-BH3BIM(I155R/E158S) at a 2.1-Å resolution (Table 1). The peptide binds to the BH3-binding groove of BCL-XL by forming an amphipathic α-helix, as observed in all of the reported structures of the BH3 peptides bound to the antiapoptotic BCL-2 family proteins14, 15, 31 (Figure 4a). Since the sequence of the p-BH3BIM(I155R/E158S) peptide is highly similar to that of the BH3 domain of mouse BIM, the presented structure can be directly compared with the structure of BCL-XL bound to the BIML BH3 domain.14 The p-BH3BIM(I155R/E158S) peptide contains four of the five consensus residues that are highly conserved in the BH3 domains of the proapoptotic proteins and known to have critical roles in interacting with the antiapoptotic BCL-2 proteins. The four residues (Ile148, Leu152, Asp157 and Phe159) in the peptide are involved in the intermolecular hydrophobic or hydrophilic interactions with BCL-XL, similar to the corresponding residues of the BIML BH3 bound to BCL-XL (not shown).

Table 1. Data collection and structure refinement statistics.

  BCL-XL−p-BIMBH3(I155R/E158S) BCL-XL−p-BIMBH3(R154S/I155R/E158S)
Space group P3221 P3
 
Unit cell dimensions
 a, b, c (Å) 72.9, 72.9, 75.5 81.7, 81.7, 42.6
 Wavelength (Å) 1.5418 0.97934
 Resolution (Å) 50–2.09 (2.13–2.09)a 50–1.65 (1.68–1.65)
 Rsymb 10.6 (23.1) 11.7 (46.6)
 I/σ(I) 34.5 (8.4) 17.3 (2.1)
 Completeness (%) 96.4 (77.5) 99.2 (94.2)
 Redundancy 6.3 6.4
 
Refinement
 Resolution (Å) 50.0–2.1 20.0–1.7
 Number of reflections 13580 34825
 Rworkc/Rfree 18.3/21.1 19.2/22.8
 
Number of atoms
 Protein 1364 2701
 Water 143 117
 Ion 6 6
 
R.M.S deviations
 Bond lengths (Å) 0.005 0.007
 Bond angles (o) 1.050 1.777
 
Ramachandran plot (%)
 Most favored region 95.3 99.4
 Additionally allowed region 4.7 0.6
 
Average B-values (Å2)
 Protein 18.4 12.3
 Peptide 18.8 11.0
 Water 27.7 19.2
Open in a new tab
a

The numbers in parentheses are statistics from the highest resolution shell.

b

Rsym=Σ |Iobs−Iavg| / Iobs, where Iobs is the observed intensity of individual reflection and Iavg is average over symmetry equivalents.

c

Rwork=Σ ||Fo|−|Fc|| / Σ |Fo|, where |Fo| and |Fc| are the observed and calculated structure factor amplitudes, respectively. Rfree was calculated with 5% of the data

Figure 4.

Figure 4

Open in a new tab

Structural analysis of the interaction between BCL-XL and p-BH3BIM(I155R/E158S). (a) Crystal structure of the BCL-XL−p-BH3BIM(I155R/E158S) complex. BCL-XL is shown as an electrostatic surface model with the bound peptide in green. For clarity, only the residues corresponding to the five consensus BH3 residues (black) and the phosphoserine (red) are labeled. The values for the electrostatic potential calculated using PyMOL50 are displayed at the bottom. (b and c) Side-by-side comparison of detailed intermolecular interactions of BCL-XL with BIML (left; PDB code 1PQ1) and with p-BH3BIM(I155R/E158S) (right). BCL-XL is in violet, and the BH3 helices are in cyan or green. (b) Ile155 contributing to the hydrophobic interactions (left) is substituted by arginine (right). (c) Phosphorylated Ser158 on the peptide is involved in electrostatic interactions with BCL-XL (right). For comparison, the numbering of BIM residues is according to that of human BIML. (d) Dual conformations of phosphorylated Ser158. The phosphoryl group of p-BH3BIM(I155R/E158S) interacts with Arg100 and Tyr101 of BCL-XL within the complex or with His177 of the neighboring BCL-XL (BCL-XL') in the crystal

The remaining consensus residue, which corresponds to Ile155 of human BIM (Ile97 of mouse BIM), is replaced by arginine in p-BH3BIM(I155R/E158S). While Ile97 of mouse BIM is involved in hydrophobic interactions with Phe97 and Tyr101 of BCL-XL, Arg155 of p-BH3BIM(I155R/E158S) forms a hydrophobic interaction with Tyr101 through its hydrocarbon portion, and makes an intramolecular salt bridge with Glu151 of the peptide through its guanidinium group (Figure 4b). The salt bridge is likely to increase the helical propensity of p-BH3BIM(I155R/E158S) in solution and to contribute to the binding affinity of this phosphorylated peptide.

Notably, the phosphate group attached to Ser158 has a dual conformation (Figures 4c right and d). In one conformation, it interacts with the guanidinium group of Arg100 and the hydroxyl group of Tyr101 of BCL-XL, where Arg100 is distantly positioned from the carboxyl group of Glu158 (5.9Å) in the structure of the BCL-XL–BIML BH3 complex14 (Figure 4c left). In the other conformation, however, the phosphate group is removed from the guanidinium group (4.6Å), and instead interacts with His177 of a symmetry-related BCL-XL molecule (3.1Å) (Figure 4d). Therefore, the observed conformation of phosphorylated Ser158 in the crystalline state would be different from the conformation of this residue in solution.

Structure of BCL-XL in complex with the p-BH3BIM(R154S/I155R/E158S) peptide

To remove the crystal packing interaction of phosphorylated Ser158, we prepared another peptide, referred to as p-BH3BIM(R154S/I155R/E158S), which contains an additional substitution of R154S in addition to the I155R and E158S substitutions (Figure 1). Arg154 was chosen for the substitution, as this residue in p-BH3BIM(I155R/E158S) was engaged in a crystal packing interaction with a symmetry mate (Supplementary Figure S1). In an ITC analysis, p-BH3BIM(R154S/I155R/E158S) exhibited slightly lower affinity for BCL-XL (KD=~40 nM) compared with p-BH3BIM(I155R/E158S) (Supplementary Figure S2). Subsequently, we obtained crystals of BCL-XL bound to this peptide in a different crystal form, and determined its structure at a 1.7Å resolution (Figure 5a and Table 1). In this crystal form, the asymmetric unit contained two copies of the complexes that exhibit nearly identical conformations (rmsd=0.063Å between 143 Cα atoms; Supplementary Figure S3). Importantly, phosphorylated Ser158 in this peptide was not involved in the crystal packing interactions. The intermolecular interactions between BCL-XL and the peptide are mostly similar to those observed in the BCL-XL–p-BH3BIM(I155R/E158S) structure (Figure 5b). In particular, phosphorylated Ser158 is in a single conformation and makes intermolecular interactions with Tyr101 and Arg100 of BCL-XL, which is likely to recapitulate the interactions in solution (Figure 5c). Together, the presented structures explain the significant enhancement of the binding affinity upon phosphorylation of Ser158 in the designed BH3BIM(I155R/E158S) peptide.

Figure 5.

Figure 5

Open in a new tab

Structural analysis of the interaction between BCL-XL and p-BH3BIM(R154S/I155R/E158S). (a) Crystal structure of the BCL-XL−p-BH3BIM(R154S/I155R/E158S) complex. BCL-XL is shown as an electrostatic surface model with the bound peptide in green. The electrostatic potential is shown at the bottom. (b) Detailed interactions of the Arg155 of p-BH3BIM(R154S/I155R/E158S) in the complex. Polar interactions are indicated by dotted lines with the distances noted. The aliphatic chain of Arg155 has a hydrophobic interaction with the Tyr101 of BCL-XL. (c) Detailed phosphoserine-mediated intermolecular interactions

Akt-dependent cytotoxic activity of the designed BH3BIM peptide

Next, we tested whether the BH3BIM(I155R/E158S) peptide exhibits cytotoxic activity. For intracellular delivery, BH3BIM(I155R/E158S) was fused to the C-terminus of the cell penetration peptide (CPP) derived from HIV Tat (Figure 1). PC3 and HCT116 cells were treated with the CPP-BH3BIM(I155R/E158S) peptide, and the MTT assay was performed. PC3 cells, which are derived from prostate cancer cells, exhibit a significantly elevated Akt activity due to the loss of PTEN, a negative regulator of Akt,32, 33 whereas the colon cancer-derived HCT116 cells exhibit a normal level of Akt activity. Seventy-two hours after the treatment with the fusion peptide, a strong cytotoxic activity was observed in the PC3 cells, but not in the HCT116 cells (Figure 6a). Immunofluorescence analysis suggested that the PC3 cells underwent apoptotic cell death (Figure 6b). Cytochrome c diffused in the cytoplasm and gradually accumulated in the nucleus, which is known to occur during apoptosis.34 In contrast, HCT116 retained the puncta staining pattern under the same treatment (Figure 6b). We then measured the activity of Akt by examining the phosphorylation state of itself and its substrate GSK3β. The CPP-BH3BIM(I155R/E158S) peptide reduced the phosphorylation of GSK3β, but not Akt itself (Figure 6c), indicating that this peptide could have acted as a substrate of Akt. To elaborate this observation, we examined the effect of the fusion peptide in three different human lung cancer cell lines. The PTEN-silenced H1299 cell lines exhibited sensitivity to the peptide, and the A549 cell line, which possesses a K-Ras mutation, showed a moderate response (Figure 6d). In contrast, the H23 cell line, which is derived from lung cancer cells with wild-type K-Ras and normal level of Akt activity, did not respond to this peptide, suggesting that the CPP-BH3BIM(I155R/E158S)-induced cell death might depend on the Akt activity. We then assessed the effect of the Akt activity by ectopically expressing wild-type Akt (Akt-WT), constitutively active Akt (myristoylated Akt; Akt-Myr) or kinase-dead-Akt (Akt-KD). Both Akt-WT and Akt-Myr promoted death of HCT116 cells, whereas Akt-KD did not show an additive effect (Figure 6e). The kinase activities of the three Akt versions were confirmed by examining GSK3β phosphorylation (Figures 6f and p-GSK3β). To know whether CPP-BH3BIM(I155R/E158S)-induced cell death might depend on BAX, the HCT116 BAX+/− and the HCT116 BAX−/− cell lines were transfected with an expression vector encoding AKT-Myr and the cells were treated with the peptide. Notably, the BAX+/− cells, but not the BAX−/− cells, were sensitized to the peptide (Figure 6g), indicating that the CPP-BH3BIM(I155R/E158S) peptide induced intrinsic apoptotic cell death via BAX. The survival of the BAX−/− cells despite the CPP-BH3BIM(I155R/E158S) treatment could be explained by an observation that the designed peptide only weakly binds to MCL-1 (not shown), which is a major inhibitor of BAK.35 Presumably, both MCL-1 and BAK are expressed in these cells.36

Figure 6.

Figure 6

Open in a new tab

CPP-fused BH3BIM(I155R/E158S) peptide induces death of PC3 cells. (a) Cell viability evaluated by the MTT assay 72 h after treatment of the peptide (0, 10 or 20 μM). N.S indicates non-significance. Error bars indicate S.D. (n=3). (b) The immunofluorescence images of PC3 and HCT116 cells treated with 20-μM CPP-BH3BIM(I155R/E158S). Cytochrome c (green) was detected by anti-cytochrome c antibody and FITC-conjugated secondary antibody, and the nucleus was stained by DAPI. The large boxes are the enlargement of the small boxes, highlighting the cytochrome c staining. (c) Western blot (WB) analysis to examine the effect of CPP-BH3BIM(I155R/E158S) on the phosphorylation of Akt (at Ser473) and GSK3β (at Ser9). PC3 cells were incubated with the peptide for 6 h at the indicated concentration. t-Akt and t-GSK3β stand for total Akt and GSK3β, respectively. (d) MTT assay to examine the cytotoxic effect of CPP-BH3BIM(I155R/E158S) on lung cancer cell lines. The viability of PTEN-silenced H1299 cells was clearly reduced by the peptide. (e) Promotion of CPP-BH3BIM(I155R/E158S)-induced death of HCT116 cells by Akt. Cells were transfected with the indicated vectors for 24 h and incubated with the peptide for 72 h. Cell death was promoted by Akt-WT and Akt-Myr, but not by Akt-KD. (f) Phosphorylation of GSK3β (p-GSK3β) by Akt-WT and Akt-Myr, but not by Akt-KD. Cells were harvested for WB after incubation with CPP-peptide for 6 h. Actin was used for loading control. (g) CPP-BH3BIM(I155R/E158S) induced apoptosis in a BAX-dependent manner. HCT116 cells and its isogenic BAX−/− cells were transfected with Akt-Myr for 24 h and incubated with the peptide at the indicated concentration for 72 h. HCT116 BAX+/− cells, but not HCT116 BAX−/− cells, were affected by the peptide

PTEN-dependent cytotoxic effect of the designed BH3BIM

For efficient cytoplasmic delivery of the proteins, we applied a novel technique of using gold nanoparticles (AuNPs) coated with anti-GST DNA aptamers.37 To apply this technique, GST-fused the BH3BIM peptides were produced and incubated with AuNPs coated with anti-GST DNA aptamer. We observed that GST-BH3BIM(I155R/E158S) efficiently killed PC3 cells (Figure 7a). In contrast, the other variants, GST-BH3BIM(E158S) and GST-BH3BIM(I155R/E158A), did not exhibit a cell-killing effect (Figure 7a), presumably because these two peptides lack either the Akt recognition sequence or a site for phosphorylation by Akt. Intriguingly, when the PTEN gene was introduced into PC3 cells by transfection, the cell-killing effect of GST-BH3BIM(I155R/E158S) was significantly reduced (Figure 7a). We confirmed that GST-BH3BIM-coated AuNPs were effectively incorporated into the cells (Figure 7b). To confirm the cytotoxic effect of each protein, we performed the trypan blue dye exclusion assay and counted viable cells. Consistent with the MTT assay described above, the AuNPs coated with GST-BH3BIM(I155R/E158S) clearly reduced the viability of PC3 cells (Figure 7c). In a control experiment, BH3BIM(I155R/E158S) and its variants did not alter the expression of proapoptotic proteins such as BAX or PUMA (Supplementary Figure S4).

Figure 7.

Figure 7

Open in a new tab

The BH3BIM(I155R/E158S) sequence induces phosphorylation-dependent cell death. (a) Cell viability by the MTT assay. One day after transfection of PC3 cells with an empty vector (EV) or a PTEN-expressing vector (PTEN), cells were treated for 12 h with AuNP-anti-GST DNA aptamer composite coated with the indicated BH3BIM peptide fused to GST (5 μM). (b) Intracellular delivery of the GST-fused peptides. Cells were washed with PBS three times to remove proteins attached to the plasma membrane. M1 stands for BH3BIM (E158S), M2 for BH3BIM (I155R/E158A), and M3 for BH3BIM (I155R/E158S). (c) Cell viability by trypan blue dye exclusion assay. To confirm the effect in (a), cells were incubated with indicated materials for 24 h and stained with trypan blue for 10 min. Percent of live cells were determined by average of 200 cells in three independent experiments. (d) Immunostaining of cytochrome c in PC3 cells. Cells were transfected (EV or PTEN), and incubated with the CPP-BH3BIM(I155R/E158S) peptide (CPP-peptide) for 48 h. Cytoplasmic puncta staining pattern was observed with PC3 cell expressing PTEN (red). In contrast, a diffused nuclear pattern was observed with EV-transfected cells. (e) PTEN blocked the cytochrome c release from mitochondria. Cells were incubated with CPP-BH3BIM(I155R/E158S) for 6 h and subjected to cell fractionation. Increase of cytoplasmic cytochrome c by CPP-BH3BIM(I155R/E158S) was obviously blocked by PTEN expression. Reduction of p-S9-GSK3β indicated competition of S9-GSK3β with the peptide for phosphorylation by PTEN. (f) PTEN also blocked PARP cleavage, an indicator of caspase activation. (g) HEK293 cells were treated in the same way as in (a). Viable cells were evaluated 48 h after the treatment by the MTT assay. Error bars indicate the S.D. (n=3)

To examine the effect of PTEN that is frequently deleted or mutated in various kinds of cancers, we ectopically expressed PTEN in PC3 cells and examined cytochrome c release. In immunostaining and cell fractionation analyses, cytochrome c release was blocked in the cells transfected with a PTEN-expressing vector, in contrast with the cells transfected with an empty vector (Figures 7d and e; Supplementary Figure S5). In fact, production of cleaved PARP, a well-known caspase 3 substrate, was abolished by PTEN transfection (Figure 7f). These results imply that BH3BIM(I155R/E158S) might be used as apoptosis inducer in PTEN-mutated cancer cells. In contrast with PC3 cells, the viability of HEK293 cells was not affected by the GST-BH3BIM-coated AuNPs, which might be ascribed to the normal activity of Akt in HEK293 cells (Figure 7g). Indeed, the AuNP-protein and the CPP-peptide slightly increased cell viability without a statistical significance (Supplementary Figure S6), indicating that the designed peptide is not harmful to untransformed cells. Together, these results demonstrate that it is possible to convert the hyperactivity of Akt in cancer cells into a death signal.

Discussion

Hyperactivation of Akt is one of the most common molecular perturbations, frequently found in many types of cancers, including glioma, non-small cell lung cancer (NSCLC), ovarian cancer and prostate cancer,28, 38, 39, 40 indicating that Akt is an attractive target for cancer therapy. Several Akt inhibitors have been developed and clinically trialed.39 However, these inhibitors seem to inevitably accompany side effects, because Akt is also important for the survival of normal cells. We described a new concept and experimental support of converting a cell-survival signal into a cell-killing apoptotic signal with an aim of killing cancer cells without affecting normal cells. These two paradoxical pathways are connected by a peptide designed to harbor the Akt recognition sequence on the potently apoptotic BIM BH3 domain. The peptide was phosphorylated by Akt as we intended, and the phosphorylated peptide interfered with the binding between BCL-2 and the PUMA BH3 domain, most likely because of its potent binding affinity for BCL-2, whereas the weakly interacting unphosphorylated peptide failed to do so. The crystal structures demonstrated how phosphorylation of Ser158 in the peptide significantly enhances the binding affinity of the peptide for BCL-XL. Remarkably, the peptide killed cancer cells exhibiting uncontrolled Akt activity, while cells bearing the normal Akt activity were unaffected.

The mode of action of the designed peptide is analogous to that of the tumor suppressor, ARF. The ARF protein leads to p53-dependent cell cycle arrest and apoptosis in response to sustained mitogenic signaling from Myc and Ras.41 The arf gene is deleted or silenced in numerous cancers, highlighting the important role of ARF as a tumor suppressor.42 Like ARF, the designed peptide might block tumor progression. We note that the RxRxxS/T motif can also be phosphorylated by RSK and S6K, which promote cell proliferation and growth.43 In certain cancer cells, the designed peptide is likely to be phosphorylated by all of the three kinases, which trigger the core Akt-RSK-S6K signaling pathways that are activated at the downstream of protooncogenic receptor protein kinases.43

The techniques for the intracellular delivery of proteins and peptides are under active development. Combined with effective techniques, the peptide or protein versions of the designed BIM BH3 variant might be developed into an anticancer drug with greatly reduced side effects. Other deregulated kinases leading to uncontrolled cell growth may also be targeted by embedding different recognition sequences in an apoptogenic BH3 sequence. In conclusion, our results represent a conceptual advance in designing peptide or protein-based cancer therapeutics that are potentiated in cancer cells, but remain dormant in normal cells.

Materials and Methods

Plasmids

The procedures for the expression of mouse BCL-XL was described previously.15 In brief, a DNA fragment coding for mouse BCL-XL (residues 1–44 and 85–196) was cloned into pProEX-HTa (Invitrogen, Carlsbad, CA, USA). To express the BH3BIM peptide and its variants as a GST-fusion protein in Escherichia coli, chemically synthesized DNA fragments encoding human BIM BH3 (residues 145-165 with appropriate mutations; BIONEER, Daejeon, South Korea) were inserted into the pGEX-TEV vector (a modified vector derived from pGEX-4T1) using the EcoRI and HindIII sites. I153R and E156S mutations were introduced into the vector by site-directed mutagenesis methods based on the overlapping PCR method. DNA fragments encoding full-length human PUMA was amplified from a human cDNA library (Life Technologies, Carlsbad, CA, USA) by a standard PCR protocol, and inserted into the pGEX-TEV vector using the EcoRI and HindIII sites. Akt and PTEN expression vectors were purchased from Addgene (Cambridge, MA, USA; PTEN, Akt-WT and Akt-Myr deposited by Dr William Sellers; Akt-KD (K179M) deposited by Dr Mien-Chie Hung)

Expression and purification of recombinant proteins

Mouse BCL-XL was purified as reported.15 In brief, the protein was expressed in the E. coli BL21(DE3) strain (Novagen, Darmstadt, Germany) at 18 °C overnight and purified by using a Ni-NTA column (Qiagen, Venlo, Limburg, Nederland) and a HiTrap Q anion exchange column (GE Healthcare, Little Chalfont, Buckinghamshire, UK). The N-terminal hexahistidine tag was cleaved with TEV protease after a Ni-NTA column purification step. GST-fused BH3BIM variants and mouse PUMA were expressed in E. coli and purified with the GST-binding agarose resin (Qiagen) equilibrated with 20-mM Tris buffer (pH 8.0) containing 150-mM NaCl and 2-mM β-mercaptoethanol. HA-tagged mouse BCL-2 was expressed from the pcDNA5/FRT/TO vector in HEK293 cells.

Peptides

The synthetic 21-mer peptides, BH3BIM(I155R/E158S), BH3BIM(R154S/I155R/E158S), p-BH3BIM (I155R/E158S), p-BH3BIM(R154S/I155R/E158S) and the CPP-fused BH3BIM(R154S/I155R/E158S) peptide (YGRRARRRARREIWIAQELRRRGDSFNAYYAR; with the underline indicating the CPP residues) were purchased from Peptron (Daejeon, South Korea). All peptides were modified to have an acetylated amino terminus and an amidated carboxyl terminus.

Crystallization and structural determination

Purified BCL-XL (4 mg/ml) in a buffer consisting of 20-mM Tris-HCl (pH 8.0), 50-mM NaCl and 1-mM dithiothreitol was mixed with p-BH3BIM(I155R/E158S) at a molar ratio of 1 : 3. The crystals of the resulting complex were obtained by the hanging-drop vapor diffusion method at 24 °C by mixing and equilibrating 1 μl of the protein solution, 1 μl of a precipitant solution containing 0.1-M sodium acetate (pH 4.8) and 3.0-M sodium chloride and 0.5 μl of 20% v/v 1,1,1,3,3,3-hexafluoro-2-propanol. Before data collection, the crystals were immersed briefly in a cryoprotectant solution, which was the reservoir solution containing additional 15% glycerol. A diffraction data set at 2.1Å was collected on R-Axis IV++ (Rigaku, Tokyo, Japan) at the Korea Research Institute of Bioscience and Biotechnology, Korea. The data set was processed using the program suit HKL2000.44 The structure was determined by the molecular replacement method with the CCP4 version of MolRep45 using the structure of the BAD BH3 peptide-bound BCL-XL46 as a search model. Subsequently, model building and refinement were carried out using the COOT47 and CNS48 programs. The final model did not include residues 32-44 of BCL-XL and the last two C-terminal residues of p-BH3BIM(I155R/E158S) whose electron densities were not observed or very weak.

For crystallization of BCL-XL bound to p-BH3BIM(R154S/I155R/E158S), the purified BCL-XL sample (18.5 mg/ml) was mixed with p-BH3BIM(R154S/I155R/E158S) at a molar ratio of 1 : 2. The crystals of the resulting complex grew in a precipitant solution containing 0.1- M sodium acetate (pH 4.6), 0.01- M calcium chloride and 15% v/v 2-methyl-2,4-pentanediol. Before data collection, the crystals were immersed briefly in a cryoprotectant solution containing additional 20% glycerol. A diffraction data set at 1.65Å was collected at the 5C beamline of the Pohang Accelerator Laboratory (PAL, Pohang, South Korea) using a QUANTUM 270 CCD detector (ADSC). The data set was processed using the program suit HKL2000.44 The structure was determined by the molecular replacement method with the CCP4 version of MolRep45 using the structure of the p-BH3BIM(I155R/E158S) peptide-bound BCL-XL as a search model. Subsequently, model building and refinement were carried out using the programs COOT47 and PHENIX.49 Figures were generated using PyMOL.50 The final model did not include residues 1 and 31-43 of BCL-XL, which are disordered in the crystal. Crystallographic data statistics are summarized in Table 1.

Isothermal titration calorimetry

All measurements were carried out at 25 °C on a microcalorimetry system iTC200 (GE Healthcare). The BCL-2 and BCL-XL samples were dialyzed against the solution containing 20 mM Tris-HCl (pH 7.5) and 350 mM NaCl. Peptides were titrated into the proteins. Dilution enthalpies were measured in separate experiments (titrant into buffer) and subtracted from the enthalpies of the binding between the protein and the titrant. Data were analyzed using the Origin software (OriginLab Corp., Northampton, MA, USA). We did three independent experiments, which gave the similar results.

In vitro kinase assay for Akt

Each reaction mixture (20 μl) contained recombinant protein substrate (9 μM), Akt/PKBa (0.4 μM) purchased from Millipore (Billerica, MA, USA), ATP (100 μM), and [γ-32P]ATP (0.5 mCi/ml) in a buffer solution containing 250 mM Tris-HCl (pH 8.0), 50 mM MgCl2 and 50 mM dithiothreitol. The mixture was incubated for 1 h at 37 °C and loaded onto a 15% SDS-PAGE gel. After electrophoresis (250 V, 37 min), the radioactivity of the gel was detected with FLA-7000 (Fujifilm, Tokyo, Japan).

Measurement of cell viability

PC3 and HEK293 cells were incubated with the GST-BH3BIM(I155R/E158S) protein conjugated to AuNP-anti-GST DNA aptamer composite37 after transfection with a PTEN expression vector (pCMV Flag WT-PTEN; addgene plasmid #22231). To examine the effect of the CPP-fused BH3BIM peptide on cell viability, PC3 and HCT116 cells were incubated with the peptide for 48 and 72 h. To examine cell viability, these cells were incubated with 0.5 mg/ml of MTT solution (Calbiochem, Darmstadt, Germany) for 4 h at 37 °C. After removing excess solution and washing with PBS, the precipitated materials were dissolved in 200 ml of dimethyl sulfoxide and quantified by measuring the absorbance at 540 nm. Each experiment was performed by at least three different researchers.

Immunofluorescence staining

Cells were seeded on a cover glass and incubated with the CCP-fused BH3BIM(I155R/E158S) peptide. After fixing with methanol for 30 min, cells were incubated with blocking buffer (0.2% (v/v) normal human antibodies in PBS) for 1 h. After extensive washing with PBS, they were incubated with 1% (v/v) anti-cytochrome c mouse antibody (BD, cat# 556432) in blocking buffer for 4 h and subsequently with 0.2% (v/v) FITC-conjugated anti-mouse Ab in PBS containing anti-human antibodies for 2 h. The nucleus was stained by DAPI. After washing with PBS, cover glasses were mounted with Vectamount (Vector Laboratories, Burlingame, CA, USA). The immunofluorescence signal was detected by fluorescence microscopy (Zeiss, Oberkochen, Germany).

Statistical analysis

Statistical significance was obtained by student's t-test.

Acknowledgments

This study was supported by grants from the National Research Foundation of Korea, funded by the Ministry of Science, ICT and Future Planning (NRF-2014R1A2A1A1105028, to NCH, the Basic Science Research Program NRF-2013R1A1A2010008 to BJP and the GRL Program 2014040003 to BHO); the Korea Research Institute of Bioscience and Biotechnology Research Initiative Program (to BK); KAIST Future Systems Healthcare Project, Ministry of Science, ICT and Future Planning (to BHO).

Glossary

BH

BCL-2 homology

MOM

mitochondrial outer membrane

ITC

isothermal titration calorimetry

AuNP

gold nanoparticle

NSCLS

non-small cell lung cancer

The authors declare no conflict of interests.

Footnotes

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)

Edited by G Dewson

Supplementary Material

Supplementary Figures
Click here for additional data file. (13.2MB, docx)

References

  1. 1Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205–219. [DOI] [PubMed] [Google Scholar]
  2. 2Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11: 621–632. [DOI] [PubMed] [Google Scholar]
  3. 3Antignani A, Youle RJ. How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane? Curr Opin Cell Biol 2006; 18: 685–689. [DOI] [PubMed] [Google Scholar]
  4. 4Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004; 305: 626–629. [DOI] [PubMed] [Google Scholar]
  5. 5Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351–365. [DOI] [PubMed] [Google Scholar]
  6. 6Kvansakul M, Hinds MG. The Bcl-2 family: structures, interactions and targets for drug discovery. Apoptosis 2015; 20: 136–150. [DOI] [PubMed] [Google Scholar]
  7. 7Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, Hsieh JJ et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 2006; 8: 1348–1358. [DOI] [PubMed] [Google Scholar]
  8. 8Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2: 183–192. [DOI] [PubMed] [Google Scholar]
  9. 9Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17: 525–535. [DOI] [PubMed] [Google Scholar]
  10. 10Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996; 381: 335–341. [DOI] [PubMed] [Google Scholar]
  11. 11Aritomi M, Kunishima N, Inohara N, Ishibashi Y, Ohta S, Morikawa K. Crystal structure of rat Bcl-xL. Implications for the function of the Bcl-2 protein family. J Biol Chem 1997; 272: 27886–27892. [DOI] [PubMed] [Google Scholar]
  12. 12Dutta S, Gulla S, Chen TS, Fire E, Grant RA, Keating AE. Determinants of BH3 binding specificity for Mcl-1 versus Bcl-xL. J Mol Biol 2010; 398: 747–762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. 13Fire E, Gulla SV, Grant RA, Keating AE. Mcl-1-Bim complexes accommodate surprising point mutations via minor structural changes. Protein Sci 2010; 19: 507–519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. 14Liu X, Dai S, Zhu Y, Marrack P, Kappler JW. The structure of a Bcl-xL/Bim fragment complex: implications for Bim function. Immunity 2003; 19: 341–352. [DOI] [PubMed] [Google Scholar]
  15. 15Ku B, Liang C, Jung JU, Oh BH. Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. Cell Res 2011; 21: 627–641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. 16Letai A. Puma strikes Bax. J Cell Biol 2009; 185: 189–191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. 17Kim H, Tu HC, Ren D, Takeuchi O, Jeffers JR, Zambetti GP et al. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell 2009; 36: 487–499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. 18Czabotar PE, Westphal D, Dewson G, Ma S, Hockings C, Fairlie WD et al. Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell 2013; 152: 519–531. [DOI] [PubMed] [Google Scholar]
  19. 19Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393–403. [DOI] [PubMed] [Google Scholar]
  20. 20Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004; 305: 1466–1470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. 21Walensky LD, Pitter K, Morash J, Oh KJ, Barbuto S, Fisher J et al. A stapled BID BH3 helix directly binds and activates BAX. Mol Cell 2006; 24: 199–210. [DOI] [PubMed] [Google Scholar]
  22. 22Labelle JL, Katz SG, Bird GH, Gavathiotis E, Stewart ML, Lawrence C et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J Clin Invest 2012; 122: 2018–2031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. 23Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008; 7: 989–1000. [DOI] [PubMed] [Google Scholar]
  24. 24Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677–681. [DOI] [PubMed] [Google Scholar]
  25. 25Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421–3428. [DOI] [PubMed] [Google Scholar]
  26. 26Hsieh AC, Truitt ML, Ruggero D. Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer 2011; 105: 329–336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. 27Kwiatkowska A, Symons M. Signaling determinants of glioma cell invasion. Adv Exp Med Biol 2013; 986: 121–141. [DOI] [PubMed] [Google Scholar]
  28. 28Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005; 94: 29–86. [DOI] [PubMed] [Google Scholar]
  29. 29Ubersax JA, Ferrell JEJr. Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol 2007; 8: 530–541. [DOI] [PubMed] [Google Scholar]
  30. 30Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997; 275: 983–986. [DOI] [PubMed] [Google Scholar]
  31. 31Oberstein A, Jeffrey PD, Shi Y. Crystal structure of the Bcl-XL-Beclin 1 peptide complex: Beclin 1 is a novel BH3-only protein. J Biol Chem 2007; 282: 13123–13132. [DOI] [PubMed] [Google Scholar]
  32. 32Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273: 13375–13378. [DOI] [PubMed] [Google Scholar]
  33. 33McCall P, Witton CJ, Grimsley S, Nielsen KV, Edwards J. Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br J Cancer 2008; 99: 1296–1301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. 34Nur EKA, Gross SR, Pan Z, Balklava Z, Ma J, Liu LF. Nuclear translocation of cytochrome c during apoptosis. J Biol Chem 2004; 279: 24911–24914. [DOI] [PubMed] [Google Scholar]
  35. 35Gelinas C, White E. BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev 2005; 19: 1263–1268. [DOI] [PubMed] [Google Scholar]
  36. 36Wang C, Youle RJ. Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak. Oncogene 2012; 31: 3177–3189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. 37Ryou S, Yeom J, Kang H, Won M, Kim J, Lee B et al. Gold nanoparticle-DNA aptamer composites as a universal carrier for in vivo delivery of biologically functional proteins. J Cont Rel 2014; 196: 287–294. [DOI] [PubMed] [Google Scholar]
  38. 38Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992; 89: 9267–9271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. 39Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 2011; 125: 627–636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. 40Al-Saad S, Donnem T, Al-Shibli K, Persson M, Bremnes RM, Busund LT. Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer. Anticancer Res 2009; 29: 4175–4183. [PubMed] [Google Scholar]
  41. 41Abida WM, Gu W. p53-Dependent and p53-independent activation of autophagy by ARF. Cancer Res 2008; 68: 352–357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. 42Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001; 2: 731–737. [DOI] [PubMed] [Google Scholar]
  43. 43Moritz A, Li Y, Guo A, Villen J, Wang Y, MacNeill J et al. Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci Signal 2010; 3: ra64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. 44Otwinosky Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 1997; 276: 307–326. [DOI] [PubMed] [Google Scholar]
  45. 45Vagin A, Teplyakov A. Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr 2010; 66: 22–25. [DOI] [PubMed] [Google Scholar]
  46. 46Ku B, Woo JS, Liang C, Lee KH, Hong HSE X et al. Structural and biochemical bases for the inhibition of autophagy and apoptosis by viral BCL-2 of murine gamma-herpesvirus 68. PLoS Pathog 2008; 4: e25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. 47Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004; 60: 2126–2132. [DOI] [PubMed] [Google Scholar]
  48. 48Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998; 54: 905–921. [DOI] [PubMed] [Google Scholar]
  49. 49Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 2010; 66: 213–221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. 50Schrodinger L. The PyMOL Molecular Graphics System, Version 1.3r1 2010.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Figures
Click here for additional data file. (13.2MB, docx)

Articles from Cell Death & Disease are provided here courtesy of Nature Publishing Group

RESOURCES